Manufacturer of Controlled Substances; Notice of Application, 36577-36578 [2011-15481]
Download as PDF
36577
Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(d)–(e) and 210.13(a),
such responses will be considered by
the Commission if received not later
than 20 days after the date of service by
the Commission of the complaint and
the notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
¨
The Sud-Chemie respondents may
present to the presiding ALJ the matter
raised in their June 6, 2011 confidential
letter to the Commission.
proposed consent decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and either
emailed to pubcommentees.enrd@usdoj.gov or mailed to P.O.
Box 7611, U.S. Department of Justice,
Washington, DC 20044–7611, and
should refer to United States v. Swift
Beef Company, Civil Action No. 8:11–
cv–216 (D. Neb.), DJ Reference No. 90–
5–1–1–09466.
During the public comment period,
the Consent Decree may also be
examined on the following Department
of Justice Web site: https://www.usdoj.
gov/enrd/Consent_Decrees.html. A copy
of the proposed consent decree may be
obtained by mailing a request to the
Consent Decree Library, P.O. Box 7611,
U.S. Department of Justice, Washington,
DC 20044–7611. When requesting a
copy by mail, please enclose a check
payable to the U.S. Treasury in the
amount of $12.00 (25 cents per page
reproduction cost). A copy may also be
obtained by faxing or e-mailing a
request to Tonia Fleetwood,
tonia.fleetwood@usdoj.gov, fax number
(202) 514–0097, phone confirmation
number (202) 514–1547, and sending a
check to the Consent Decree Library at
the stated address.
By order of the Commission.
Issued: June 16, 2011.
James R. Holbein,
Secretary to the Commission.
Robert E. Maher, Jr.,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2011–15534 Filed 6–21–11; 8:45 am]
[FR Doc. 2011–15465 Filed 6–21–11; 8:45 am]
BILLING CODE 7020–02–P
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Notice of Lodging of Consent Decree
Pursuant to the Clean Water Act
Notice is hereby given that on June
16, a proposed Consent Decree in
United States and the State of Nebraska
v. Swift Beef Company, Civil Action No.
8:11–cv–216 was lodged with the
United States Court for the District of
Nebraska. In this action, Plaintiffs the
United States and State of Nebraska
sought the penalties and injunctive
relief for violations of the Clean Water
Act (‘‘CWA’’) by Swift Beef Company
(‘‘Swift’’) at a beef processing plant it
owns and operates in Grand Island,
Nebraska. Pursuant to the proposed
Consent Decree, Defendants will pay to
the United States and the State of
Nebraska $1,300,000 in civil penalties
and undertake injunctive measures
designed to prevent future violations.
For 30 days after the date of this
publication, the Department of Justice
will receive comments relating to the
VerDate Mar<15>2010
16:40 Jun 21, 2011
Jkt 223001
Drug Enforcement Administration
for distribution and sale to its
customers. Regarding (9640) the
company plans to manufacture another
controlled substance for sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 22, 2011.
Dated: June 14, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–15478 Filed 6–21–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 4, 2011,
Boehringer Ingelheim Chemicals Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805–9372, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 11, 2011,
Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Chattanooga, Tennessee 37409,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Tapentadol (9780) ........................
I
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Drug
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Schedule
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
E:\FR\FM\22JNN1.SGM
22JNN1
36578
Federal Register / Vol. 76, No. 120 / Wednesday, June 22, 2011 / Notices
Springfield, Virginia 22152; and must be
filed no later than August 22, 2011.
Dated: June 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–15481 Filed 6–21–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 9, 2011, and
published in the Federal Register on
March 17, 2011, 76 FR 14689,
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Drug Schedule.
Methylphenidate (1724) ................
Nabilone (7379) ............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
VerDate Mar<15>2010
16:40 Jun 21, 2011
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 223001
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Mallinckrodt, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: June 14, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–15482 Filed 6–21–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
156th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of Meeting
Pursuant to the authority contained in
Section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 156th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans; (also
known as the ERISA Advisory Council)
will be held on July 19–21, 2011.
The three-day meeting will take place
in C–5515 Room 1–A, U.S. Department
of Labor, 200 Constitution Avenue,
NW., Washington, DC 20210. The
purpose of the open meeting is for
Advisory Council members to hear
testimony from invited witnesses and to
receive an update from the Employee
Benefits Security Administration
(EBSA). The meeting will run from
9 a.m. to approximately 5 p.m. on July
19 and from 8:30 a.m. to approximately
5 p.m. on July 20 and 21, with a one
hour break for lunch each day. The
EBSA update is scheduled for the
afternoon of July 20, subject to change.
PO 00000
Frm 00067
Fmt 4703
Sfmt 9990
The Advisory Council will study the
following issues: (1) Hedge Funds and
Private Equity Investments, (2) Privacy
and Security Issues Affecting Employee
Benefit Plans (other than health care
plans), and (3) Current Challenges and
Best Practices for ERISA Compliance for
403(b) Plan Sponsors. The schedule for
testimony and discussion of these issues
generally will be one issue per day in
the order noted above. Descriptions of
these topics are available on the
Advisory Council page of the EBSA Web
site, at https://www.dol.gov/ebsa/
aboutebsa/erisa_advisory_council.html.
Organizations or members of the
public wishing to submit a written
statement may do so by submitting 30
copies on or before July 12, 2011 to
Larry Good, Executive Secretary, ERISA
Advisory Council, U.S. Department of
Labor, Suite N–5623, 200 Constitution
Avenue, NW., Washington, DC 20210.
Statements also may be submitted as
e-mail attachments in text or pdf format
transmitted to good.larry@dol.gov. It is
requested that statements not be
included in the body of the e-mail.
Statements deemed relevant by the
Advisory Council and received on or
before July 12, 2011 will be included in
the record of the meeting and available
in the EBSA Public Disclosure room,
along with witness statements. Do not
include any personally identifiable
information (such as name, address, or
other contact information) or
confidential business information that
you do not want publicly disclosed.
Written statements submitted by invited
witnesses also will be posted, without
change, on the Advisory Council page of
the EBSA Web site—https://
www.dol.gov/ebsa/. Statements posted
on the Internet can be retrieved by most
Internet search engines.
Individuals or representatives of
organizations wishing to address the
Advisory Council should forward their
requests to the Executive Secretary or
telephone (202) 693–8668. Oral
presentations will be limited to ten
minutes, time permitting, but an
extended statement may be submitted
for the record. Individuals with
disabilities who need special
accommodations should contact the
Executive Secretary by July 12 at the
address indicated.
Signed at Washington, DC, this 17th day of
June 2011.
Michael L. Davis,
Deputy Assistant Secretary, Employee
Benefits Security Administration.
[FR Doc. 2011–15587 Filed 6–21–11; 8:45 am]
BILLING CODE 4510–29–P
E:\FR\FM\22JNN1.SGM
22JNN1
Agencies
[Federal Register Volume 76, Number 120 (Wednesday, June 22, 2011)]
[Notices]
[Pages 36577-36578]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-15481]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 4, 2011, Boehringer
Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia
23805-9372, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers for formulation into finished
pharmaceuticals.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive,
[[Page 36578]]
Springfield, Virginia 22152; and must be filed no later than August 22,
2011.
Dated: June 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-15481 Filed 6-21-11; 8:45 am]
BILLING CODE 4410-09-P